Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

NCT04423029 is registered in ClinicalTrials.gov with Dragonfly Therapeutics as lead sponsor.

NCT NCT04423029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04423029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Lead sponsor
Dragonfly Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
July 13, 2020
Completion date
November 26, 2025
Enrollment
170 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors